Does type of bolus insulin matter in the hospital? Retrospective cohort analysis of outcomes between patients receiving analogue versus human insulin

Clinical Therapeutics

Volumn 32, Issue 11, 2010, Pages 1954-1966

  Ko, Kelly J ^a   Tomor, Veronica ^b   Nathanson, Brian H ^c   Bouchard, Jonathan R ^b   Aagren, Mark ^b   Dubois, Robert W ^a,d  

^a CERNER CORPORATION   (United States)

^b NOVO NORDISK INC   (United States)

^c OptiStatim LLC   (United States)

^d National Pharmaceutical Council   (United States)

Author keywords

Analogue; Bolus insulin; Glycemic control

Indexed keywords

GLUCOSE; HUMAN INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN GLULISINE; INSULIN LISPRO;

ARTICLE; BOLUS INJECTION; CLINICAL TRIAL; COHORT ANALYSIS; DIABETES MELLITUS; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HOSPITAL PATIENT; HOSPITALIZATION COST; HUMAN; INSULIN TREATMENT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOMES RESEARCH; RETROSPECTIVE STUDY; SCORING SYSTEM;

AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; COHORT STUDIES; DATABASES, FACTUAL; FEMALE; HOSPITAL MORTALITY; HOSPITALIZATION; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LENGTH OF STAY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPENSITY SCORE; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES;

EID: 78649345273     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2010.10.009     Document Type: Article

References (32)

1. Garber AJ, Moghissi ES, Bransome ED, et al. American College of Endocrinology position statement on inpatient diabetes and metabolic control. Endocr Pract. 2004, 10:77-82. American College of Endocrinology Task Force on Inpatient Diabetes Metabolic Control.
2. Umpierrez GE, Isaacs SD, Bazargan N, et al. Hyperglycemia: An independent marker of in-hospital mortality in patients with undiagnosed diabetes. J Clin Endocrinol Metab. 2002, 87:978-982.
3. Standards of medical care in diabetes-2006 [published correction appears in Diabetes Care. 2006;29:1192]. Diabetes Care. 2006, 29(Suppl 1):S4-S42. American Diabetes Association.
4. van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med. 2001, 345:1359-1367.
5. Clement S, Braithwaite SS, Magee MF, et al. Management of diabetes and hyperglycemia in hospitals [published correction appears in Diabetes Care. 2004;27:1255 and Diabetes Care. 2004;27: 856]. Diabetes Care. 2004, 27:553-591. American Diabetes Association Diabetes in Hospitals Writing Committee.
6. Turchin A, Matheny ME, Shubina M, et al. Hypoglycemia and clinical outcomes in patients with diabetes hospitalized in the general ward. Diabetes Care. 2009, 32:1153-1157.
7. Umpierrez GE, Smiley D, Zisman A, et al. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial). Diabetes Care. 2007, 30:2181-2186.
8. Malmberg K Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. BMJ. 1997, 314:1512-1515. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group.
9. Hirsch IB Insulin analogues. N Engl J Med. 2005, 352:174-183.
10. Knecht LA, Gauthier SM, Castro JC, et al. Diabetes care in the hospital: Is there clinical inertia?. J Hosp Med. 2006, 1:151-160.
11. Schnipper JL, Barsky EE, Shaykevich S, et al. Inpatient management of diabetes and hyperglycemia among general medicine patients at a large teaching hospital. J Hosp Med. 2006, 1:145-150.
12. Hartman I Insulin analogs: Impact on treatment success, satisfaction, quality of life, and adherence. Clin Med Res. 2008, 6:54-67.
13. Howey DC, Bowsher RR, Brunelle RL, Woodworth JR [Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin. Diabetes. 1994, 43:396-402.
14. Mudaliar SR, Lindberg FA, Joyce M, et al. Insulin aspart (B28 asp-insulin): A fast-acting analog of human insulin: Absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. Diabetes Care. 1999, 22:1501-1506.
15. Bretzel RG, Arnolds S, Medding J, Linn T A direct efficacy and safety comparison of insulin aspart, human soluble insulin, and human premix insulin (70/30) in patients with type 2 diabetes. Diabetes Care. 2004, 27:1023-1027.
16. Heller SR, Colagiuri S, Vaaler S, et al. Hypoglycaemia with insulin aspart: A double-blind, randomised, crossover trial in subjects with Type 1 diabetes. Diabet Med. 2004, 21:769-775.
17. Krones R, Schütte C, Heise T The rapid-acting properties of insulin aspart are preserved in elderly people with type 2 diabetes. Diabetes Obes Metab. 2009, 11:41-44.
18. Bartolo PD, Pellicano F, Scaramuzza A, et al. Better postprandial glucose stability during continuous subcutaneous infusion with insulin aspart compared with insulin lispro in patients with type 1 diabetes. Diabetes Technol Ther. 2008, 10:495-498.
19. Siebenhofer A, Plank J, Berghold A, et al. Short acting in- sulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database Syst Rev. 2006, (2):CD003287.
20. HIPAA privacy rule and public health. Guidance from CDC and the U.S. Department of Health and Human Services. MMWR Morb Mortal Wkly Rep. 2003, 52(Suppl 1):1-17. Centers for Disease Control and Prevention (CDC).
21. HIPAA privacy rule and public health. Guidance from CDC and the U.S. Department of Health and Human Services. MMWR Morb Mortal Wkly Rep. 2003, 52(Suppl 1):19-20. Centers for Disease Control and Prevention (CDC).
22. Lindenauer PK, Rothberg MB, Nathanson BH, et al. Activated protein C and hospital mortality in septic shock: A propensity-matched analysis. Crit Care Med. 2010, 38:1101-1107.
23. Wooldridge JM Econometric Analysis of Cross Section and Panel Data 2002, MIT Press, Cambridge, Mass.
24. Williams RL A note on robust variance estimation for cluster-correlated data. Biometrics. 2000, 56:645-646.
25. Harrell FE Regression Modeling Strategies with Applications to Linear Models, Logistic Regression, and Survival Models 2001, SpringerVerlag, New York, NY.
26. Lin DY, Psaty BM, Kronmal RA Assessing the sensitivity of regression results to unmeasured confounders in observational studies. Biometrics. 1998, 54:948-963.
27. Peikes DN, Moreno L, Orzol SM Propensity Score Matching: A note of caution for evaluators of social programs. Am Stat. 2008, 62:222-231.
28. Yendamuri S, Fulda GJ, Tinkoff GH Admission hyperglycemia as a prognostic indicator in trauma. J Trauma. 2003, 55:33-38.
29. Rovlias A, Kotsou S The influence of hyperglycemia on neurological outcome in patients with severe head injury. Neurosurgery. 2000, 46:335-342. discussion.
30. Rovlias A, Kotsou S The influence of hyperglycemia on neurological outcome in patients with severe head injury. Neurosurgery. 2000, 46:342-343.
31. Krinsley JS, Grover A Severe hypoglycemia in critically ill patients: Risk factors and outcomes. Crit Care Med. 2007, 35:2262-2267.
32. Ryan EA, Shandro T, Green K, et al. Assessment of the severity of hypoglycemia and glycemic lability in type 1 diabetic subjects undergoing islet transplantation. Diabetes 2004, 53:955-962.